11 Reksa Dana Terbaik dengan 006280 / GC Biopharma Corp. (KOSE)

GC Biopharma Corp.
KR ˙ KOSE ˙ KR7006280002
₩ 131,000.00 ↓ -900.00 (-0.68%)
2025-09-05
BAHAGING PRESYO
11 Reksa Dana Terbaik dengan KR:006280 / GC Biopharma Corp.

Halaman ini menampilkan semua reksa dana yang telah melaporkan posisi di KR:006280 / GC Biopharma Corp.. Baris berwarna hijau menunjukkan posisi baru. Klik tautan ikon untuk melihat riwayat transaksi selengkapnya.

Tingkatkan ke versi premium untuk membuka data premium dan ekspor ke Excel. .

Tanggal File Sumber Investor Ketik Presyo ng Avg
(Silangan)
Saham Δ Saham
(%)
Dilaporkan
Nilai
($1000)
Nilai Δ
(%)
Alokasi Port
(%)
2025-06-26 NP DAADX - Emerging Markets ex China Core Equity Portfolio Institutional Class 703 0.00 61 -7.58
2025-06-26 NP DFCEX - Emerging Markets Core Equity Portfolio - Institutional Class This fund is a listed as child fund of Dimensional Fund Advisors Lp and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 25,112 0.00 2,191 -7.59
2025-03-26 NP SFILX - Schwab Fundamental International Small Company Index Fund Institutional Shares This fund is a listed as child fund of Charles Schwab Investment Management Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 326 -50.53 31 -61.04
2025-06-26 NP FTIHX - Fidelity Total International Index Fund This fund is a listed as child fund of Fmr Llc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 3,284 -20.79 286 -26.92
2025-08-28 NP SSGVX - State Street Global Equity ex-U.S. Index Portfolio State Street Global All Cap Equity ex-U.S. Index Portfolio This fund is a listed as child fund of State Street Corp and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 1,262 0.00 118 12.38
2025-08-25 NP EITEX - Parametric Tax-Managed Emerging Markets Fund Institutional Class 1,257 0.00 117 12.50
2025-04-18 NP AVEEX - Avantis Emerging Markets Equity Fund Institutional Class This fund is a listed as child fund of American Century Companies Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 210 0.00 18 -18.18
2025-08-27 NP VTMGX - Vanguard Developed Markets Index Fund Admiral Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 50,801 5.05 4,744 17.63
2025-06-30 NP VPACX - Vanguard Pacific Stock Index Fund Investor Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 6,626 0.00 578 -7.52
2025-06-26 NP OWSMX - Old Westbury Small & Mid Cap Strategies Fund 42,263 0.00 3,688 -7.59
2025-06-30 NP VGTSX - Vanguard Total International Stock Index Fund Investor Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value 77,163 0.00 6,733 -7.59
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista